key: cord-0302572-9j9tzg34 authors: Spouge, John L. title: Recent SIV-Macaque Trials: A Reassessment of Immune Priming and Varying Infectability in Repeated Low-dose Challenge Studies date: 2021-07-28 journal: bioRxiv DOI: 10.1101/2021.07.28.454270 sha: d7b6797fb0a8750b4f7ab92fffe63356567848c5 doc_id: 302572 cord_uid: 9j9tzg34 Nowadays, most preclinical HIV treatment trials use a protocol of administering repeated low-dose challenges (RLCs) of simian immunodeficiency virus (SIV) to macaques. Statistical analyses of treatment efficacy under the RLC protocol need to consider two confounding hypotheses, both pertinent biologically to HIV: (1) the non-infecting challenges may immunize animals against SIV; and (2) the animals may vary in intrinsic infectability (“frailty”). To explore the two hypotheses, a previous study (Regoes 2012) assembled a database from 7 articles with SIV-macaque treatment trials. With two explicable exceptions, Regoes concluded that the control data did not support either confounding hypothesis. Recent SIV-macaque trials present opportunities to evaluate the conclusions’ robustness. Accordingly, the present article assembles from 24 articles an updated database containing net survival curves from both control and treatment arms in SIV-macaque treatment trials. Broad patterns of statistical significance (at p<0.05, uncorrected for multiple testing) made it difficult to dismiss the confounding hypotheses completely in the controls. Although statistical analysis has focused on defense against variable frailty, only one set of controls showed significant variable frailty, whereas many sets showed significant immunization. As trials progressed, changes in the probability of infection per challenge were significant in 8/28 trials (1/3 trials using oral challenges; 2/4 trials using vaginal challenges; and 5/21 trials using rectal challenges). The results suggest the possibility that vaginal challenges may immunize animals faster than rectal challenges, and they also bear on previous conclusions that repeated exposure to HIV without treatment may have no effect on infectability or may even reduce it. Author Summary Many preclinical trials of HIV treatments rely on repeatedly administering low-dose SIV challenges to macaques until infection occurs. The repeated low-dose protocol reuses macaques and is more sensitive to subtle therapeutic efficacies than a protocol administering a single large dose to each macaque. The animal reuse raises some pertinent biological questions, notably: (1) do macaques have intrinsically variable infectabilities? and (2) do the repeated SIV challenges immunize macaques against infection? A 2012 study collected a database of eight macaque trials, concluding that variable infectability and immunization were at most sporadic and readily explicable. I expanded the 2012 database to twenty-eight trials, discovering that the conclusions were not robust. Although only 1/28 SIV-macaque trials showed variable infectability, 7/28 showed immunization, with few ready explanations. Statistical analysis of SIV-macaque trials has focused on the confounding effects of variable infectability to the neglect of immunization, so the expanded database provides a rich empirical resource. The trials have general medical importance because they provide a model for analyzing animal trials of infectious disease therapies and other sparse trials, e.g., for breast cancer. My findings also indirectly suggest that repeated human exposure to HIV inconsistently immunizes and can foster either immune priming or tolerance. The RLC protocol has regularities not available in clinical trials, notably compulsory follow 151 up and a possibility that between observations, all hazards to controls may be roughly the same, Table 1 presents the metadata of the SIV-Macaque database. Each row corresponds to a 174 single control arm and its trial. The columns indicate: (1) the citation in the present article; (2) its 175 first author; (3) its year of publication; (4) its ID in PubMed; (5) the source within it for each set 176 of controls (a citation may contain more than one trial and therefore more than one source of 177 data); (6) the virus used to challenge; (7) the species of macaque challenged; (8) the challenge 178 route; and (9) the number of weeks between the regular challenges. In the final 3 columns, 179 uncommon values are highlighted in yellow, e.g., the Ellenberger (2006) 216 In the final 7 columns, any p-value less than 0.05 is highlighted in yellow. 217 Table 3 Tables 3 and 4 235 displayed only a few anomalous rows with p<0.05, consistent with his conclusion that a constant The trials in Table 3 outside Regoes' Tables 3 and 4 The SIV-Macaque database and I acknowledge the invaluable aid of Ms. Chelsea Zebaze in digitizing data from animal trials and 516 several useful conversations with Dr DoHwan Park and Dr Junyong Park Nonhuman Primate Models and Understanding the Pathogenesis of 521 HIV Infection and AIDS Challenge of 523 chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein 524 gp120 Statistical-Analysis of Sparse Infection Data and Its Implications For Retroviral 526 Treatment Trials in Primates Parsimonious Determination of the Optimal Infectious Dose of a Pathogen for Nonhuman Primate Models Nonparametric Statistics for the Behavioral Sciences NIH to End Chimp Breeding for Research Progress reported on mouse models for AIDS Benefits and limitations of humanized mice in HIV persistence studies Increased mortality and 536 AIDS-like immunopathology in wild chimpanzees infected with SIVcpz A Period of Transient Viremia and Occult Infection Precedes Persistent Viremia and Antiviral Immune Responses during Multiple Low-Dose 539 Intravaginal Simian Immunodeficiency Virus Inoculations Simian Immunodeficiency Virus (SIV) Vaccines Given in Infancy Partially Protect Infant 542 and Juvenile Macaques Against Repeated Oral Challenge With Virulent SIV HIV-1 DNA/MVA 545 vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges Vaccine-induced 548 cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with 549 pathogenic simian immunodeficiency virus SIVmac239 Prevention of 551 rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and 552 tenofovir Effector 554 memory T cell responses are associated with protection of rhesus monkeys from mucosal simian 555 immunodeficiency virus challenge Vaccine-induced 557 cellular responses control simian immunodeficiency virus replication after heterologous challenge Effective, low-560 titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques Macaques 563 vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control 564 replication after repeated low-dose heterologous SIV challenge Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys Profound 569 early control of highly pathogenic SIV by an effector memory T-cell vaccine Vaccine protection against 572 acquisition of neutralization-resistant SIV challenges in rhesus monkeys Antibodies with high avidity 574 to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) 575 acquisition in an immunization regimen that mimics the RV-144 Thai trial Cutting edge: novel 577 vaccination modality provides significant protection against mucosal infection by highly pathogenic 578 simian immunodeficiency virus Immunological 580 and virological mechanisms of vaccine-mediated protection against SIV and HIV Combination Emtricitabine 583 and Tenofovir Disoproxil Fumarate Prevents Vaginal Simian/Human Immunodeficiency Virus Infection 584 in Macaques Harboring Chlamydia trachomatis and Trichomonas vaginalis Adjuvant-587 dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition Antibody Responses Are Associated with Reduced Simian Immunodeficiency 591 Viremia in Infant Rhesus Macaques Medroxyprogesterone Acetate Dose That Models Human Use and Its Effect on Vaginal SHIV 594 Acquisition Risk Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits 597 Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens 601 Strongly Inhibits Early Viral Replication Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant 604 Macaques. mSphere HIV vaccine 606 candidate activation of hypoxia and the inflammasome in CD14(+) monocytes is associated with a 607 decreased risk of SIV(mac251) acquisition HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous 610 SHIV challenge Power to detect the 612 effects of HIV vaccination in repeated low-dose challenge experiments The role of exposure history on HIV acquisition: insights from repeated low-dose 614 challenge studies Preclinical assessment of HIV vaccines and 616 microbicides by repeated low-dose virus challenges Monkeying around with HIV vaccines: using rhesus 618 macaques to define 'gatekeepers' for clinical trials Toward a Macaque Model of HIV-1 Infection Heterogeneity's ruses: some surprising effects of selection on population 622 dynamics Assessing vaccine effects in repeated low-dose challenge experiments A discrete-time survival model with random effects for designing 626 and analyzing repeated low-dose challenge experiments Analysis of Repeated Low-Dose Challenge Studies Exact log-rank tests for unequal follow-up Nonparametric-Estimation from Incomplete Observations Meta-evaluation of meta-analysis: ten 634 appraisal questions for biologists 2 Notes on Notation On testing for a constant hazard against a change-point alternative A frailty mixture model for estimating vaccine efficacy Asymptotic Properties of Maximum-Likelihood Estimators and Likelihood 642 Ratio Tests under Nonstandard Conditions Analysis of Binary Data Escape Mutations in the Capsid Are Transferable between Simian Immunodeficiency Virus Strains. 646 HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response Equivalence of the mediation, confounding and 651 suppression effect This is an index for the Supporting Information This contains additional methods and a legend for This table includes Tables 1-3 and other information in 661 floating-point precision This is a directory containing the CSV files, 664 DataFrames containing the data from the net survival curves in the SIV-Macaque 665 database